The mean levels of glycosylated hemoglobin decreased by 1.0 % in the 4 mg/d metformin-rosiglitazone group and by 1.2 % in the 8 mg/d metformin-rosiglitazone group and fasting plasma glucose levels by 2.2 mmol/L ( 39.8 mg/dL ) and 2.9 mmol/L ( 52.9 mg/dL ) compared with the metformin-placebo group ( P < .001 for all ) .
